



US008956849B2

(12) **United States Patent**
Bottje et al.(10) **Patent No.:** **US 8,956,849 B2**
(45) **Date of Patent:** **Feb. 17, 2015**(54) **COMPOSITIONS AND METHODS OF
ENHANCING IMMUNE RESPONSES TO
EIMERIA**(75) Inventors: **Walter Bottje**, Fayetteville, AR (US);
Billy Hargis, Fayetteville, AR (US); **Luc
Berghman**, College Station, TX (US);
Young Min Kwon, Springdale, AR
(US); **Kimberly Cole**, Raymond, OH
(US); **Mandy Cox**, Fayetteville, AR
(US); **Sherryll Layton**, Fayetteville, AR
(US); **Said El-Ashram**, Guelph (CA);
John Barta, Guelph (CA); **Guillermo
Tellez**, Fayetteville, AR (US)(73) Assignees: **The Board of Trustees of the
University of Arkansas**, Little Rock, AR
(US); **The Texas A&M University
System**, College Station, TX (US); **The
University of Guelph**, Guelph, Ontario
(CA)(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 1171 days.(21) Appl. No.: **12/740,608**(22) PCT Filed: **Nov. 3, 2008**
(Under 37 CFR 1.47)(86) PCT No.: **PCT/US2008/082254**
§ 371 (c)(1),
(2), (4) Date: **Dec. 28, 2010**(87) PCT Pub. No.: **WO2009/059298**
PCT Pub. Date: **May 7, 2009**(65) **Prior Publication Data**

US 2011/0111015 A1 May 12, 2011

Related U.S. Application Data(60) Provisional application No. 60/984,612, filed on Nov.
1, 2007.(51) **Int. Cl.**
C07H 21/04 (2006.01)
C07H 21/02 (2006.01)
C12N 7/00 (2006.01)
C12N 7/01 (2006.01)
C12N 15/00 (2006.01)
C07K 14/705 (2006.01)
C07K 14/455 (2006.01)
A61K 39/00 (2006.01)(52) **U.S. Cl.**
CPC **C07K 14/70575** (2013.01); **C07K 14/455**
(2013.01); **A61K 2039/523** (2013.01); **A61K**
2039/53 (2013.01); **C07K 2319/03** (2013.01)
USPC **435/235.1**; 435/320.1; 536/23.1;
536/23.7(58) **Field of Classification Search**
CPC A61K 2039/53; A61K 48/00; A61K2039/5256; A61K 2039/5156; A61K 2039/523;
A61K 38/00; A61K 2300/00; A61K 48/005;
A61K 48/0058; C12N 15/86; C12N
2710/10343; C12N 15/861; C12N 15/863;
C12N 15/8633; C12N 15/867; C07K 14/455;
C07K 2319/03

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,540,926 A * 7/1996 Aruffo et al. 424/153.1
5,565,321 A * 10/1996 Spriggs et al. 435/6.16
5,683,700 A 11/1997 Charles et al.
5,716,805 A * 2/1998 Srinivasan et al. 435/69.1
5,747,309 A 5/1998 Allan et al.
5,817,516 A * 10/1998 Kehry et al. 435/377
5,961,974 A * 10/1999 Armitage et al. 424/154.1
5,962,406 A 10/1999 Armitage et al.
5,981,724 A 11/1999 Armitage et al.
6,087,329 A 7/2000 Armitage et al.
6,190,669 B1 2/2001 Noriega et al.
6,264,951 B1 7/2001 Armitage et al.
6,290,972 B1 9/2001 Armitage et al.
6,306,387 B1 10/2001 Galan
6,410,711 B1 6/2002 Armitage et al.
6,479,258 B1 11/2002 Short
6,713,279 B1 3/2004 Short
6,902,906 B1 6/2005 Chatfield
6,923,957 B2 8/2005 Lowery et al.
6,923,958 B2 8/2005 Xiang et al.
6,936,425 B1 8/2005 Hensel et al.
6,969,609 B1 11/2005 Schlom et al.
7,087,573 B1 8/2006 Lazarus et al.
7,118,751 B1 * 10/2006 Ledbetter et al. 424/192.1
7,238,499 B2 * 7/2007 Reddy 435/69.7
7,332,298 B2 2/2008 Kornbluth
7,371,392 B2 5/2008 Tripp et al.
7,405,270 B2 7/2008 Armitage et al.
7,423,137 B2 * 9/2008 Belli et al. 536/23.7
7,462,707 B1 * 12/2008 Witcombe et al. 536/23.7

(Continued)

FOREIGN PATENT DOCUMENTS

WO WO 93/08207 4/1993
WO WO 95/14487 6/1995

(Continued)

OTHER PUBLICATIONS

Webster et al, Vaccine , 2006, 24:3026-3034.*

(Continued)

Primary Examiner — Nita M Minnifield

(74) Attorney, Agent, or Firm — Andrus Intellectual
Property Law, LLP(57) **ABSTRACT**Vaccines comprising TRAP polypeptides and *Salmonella*
enteritidis vectors comprising TRAP polypeptides are pro-
vided. The vaccines may also include a CD154 polypeptide
capable of binding to CD40. Also provided are methods of
enhancing an immune response against Apicomplexan para-
sites and methods of reducing morbidity associated with
infection with Apicomplexan parasites.**26 Claims, 3 Drawing Sheets**

(56)

References Cited

U.S. PATENT DOCUMENTS

7,495,090	B2	2/2009	Prussak et al.	
7,803,765	B2 *	9/2010	Watt et al.	514/1.2
7,842,501	B2	11/2010	Cai et al.	
7,928,213	B2	4/2011	Prussak et al.	
7,968,695	B2 *	6/2011	Belli et al.	536/23.7
8,142,771	B2 *	3/2012	Suo et al.	424/93.21
8,318,310	B2 *	11/2012	Bernard et al.	428/423.1
8,604,178	B2 *	12/2013	Bottje et al.	536/23.7
2001/0021386	A1	9/2001	Nuijten et al.	
2003/0091584	A1 *	5/2003	Young et al.	424/186.1
2004/0006006	A9	1/2004	Armitage et al.	
2004/0047873	A1	3/2004	Al-Shamkhani et al.	
2004/0203039	A1	10/2004	Hensel et al.	
2005/0033042	A1 *	2/2005	Belli et al.	536/23.7
2005/0181994	A1	8/2005	Chamberlain et al.	
2005/0226888	A1	10/2005	Deisseroth et al.	
2006/0014248	A1	1/2006	Marshall et al.	
2006/0078994	A1	4/2006	Healey et al.	
2006/0233829	A1	10/2006	Curtiss	
2006/0286074	A1	12/2006	Tang et al.	
2007/0025982	A1	2/2007	Ledbetter et al.	
2007/0082400	A1	4/2007	Healey et al.	
2007/0128223	A1	6/2007	Tang et al.	
2007/0237779	A1	10/2007	Ledbetter et al.	
2009/0004194	A1	1/2009	Kedl	
2009/0196888	A1 *	8/2009	Belli et al.	424/267.1
2009/0324644	A1 *	12/2009	Ramos et al.	424/209.1
2010/0047231	A1	2/2010	Zabaleta Azpiroz et al.	
2010/0112002	A1	5/2010	Lien et al.	
2010/0150958	A1 *	6/2010	Sheppard	424/201.1
2010/0163668	A1 *	7/2010	Nannoni et al.	244/17.21
2010/0291109	A1	11/2010	Kedl	
2010/0292309	A1	11/2010	Vile et al.	
2011/0111015	A1 *	5/2011	Bottje et al.	424/450
2012/0282291	A1 *	11/2012	Berghman et al.	424/192.1

FOREIGN PATENT DOCUMENTS

WO	WO 96/26735	9/1996
WO	WO 96/40918	12/1996
WO	WO 99/27948	6/1999
WO	WO 99/32138	7/1999
WO	WO 00/63395	10/2000
WO	WO 00/63405	10/2000
WO	WO 01/42298	6/2001
WO	WO 01/56602	8/2001
WO	WO 02/36769	5/2002
WO	WO 02/092773	11/2002
WO	WO 03/004683	1/2003
WO	WO 03/004684	1/2003
WO	WO 03/099340	12/2003
WO	WO 2004/009615	1/2004
WO	WO 2005/035570	4/2005
WO	WO 2005/058950	6/2005
WO	WO 2005/113598	12/2005
WO	WO 2006/042177	4/2006
WO	WO 2006/105972	10/2006
WO	WO 2007/042583	4/2007
WO	WO 2007/054658	5/2007
WO	WO 2007/056266	5/2007
WO	WO 2007/103048	9/2007
WO	WO 2007/117682	10/2007
WO	WO 2008/036675	3/2008
WO	WO 2008/109825	9/2008
WO	WO 2009/059018	5/2009

OTHER PUBLICATIONS

Skolnick et al. (Trends in Biotech., 18(1):34-39, 2000).*

Greenspan et al (Nature Biotechnology 7: 936-937, 1999).*

Chothia et al (The EMBO Journal, 1986, 5/4:823-26).*

Babu, U., et al., "Salmonella enteritidis clearance and immune responses in chickens following Salmonella vaccination and challenge," Vet. Immunol. Immunopathol. (2004)101:251-257.

Chatfield et al., "The development of oral vaccines based on live attenuated *Salmonella* strains," FEMS Immunol. Med. Microbiol. (1993) 7:1-7.

Fernandez-Cabezudo et al., "Evidence for the requirement for CD40-CD154 interactions in resistance to infections with attenuated *Salmonella*," J. Endotoxin Res. (2005) 11:395-399.

Kaiser, J., "A one-size-fits-all flu vaccine?," Science (2006) 312:380-382.

Lavelle, E.C. et al., "Deliver systems and adjuvants for oral vaccines," Expert Opin. Drug Deliv. (2006) 3(6):747-762.

Lee, J. et al., "Mucosal immunization with surface-displayed severe acute respiratory syndrome coronavirus spike protein on *Lactobacillus casei* induces neutralizing antibodies in mice," J. Virol. (2006) 80:4079-4087.

Mann, J.F. et al., "Delivery systems: a vaccine strategy for overcoming mucosal tolerance?" Expert Rev. Vaccines (2009) 8(1)103-112.

Mohamadzadeh, M, et al., "Targeting mucosal dendritic cells with microbial antigens from probiotic lactic acid bacteria," Expert Rev. Vaccines (2008) 7(2):163-174 (Abstract).

Moyle, P.M. et al., "Mucosal immunisation: adjuvants and delivery systems," Curr. Drug Deliv. (2004) 1(4):385-396 (Abstract).

Rovere-Querini, P. et al., "HMGB1 is an endogenous immune adjuvant released by necrotic cells," EMBO Rep. (2004) 5(8):825-830.

Swayne, D.E. et al., "Protection against diverse highly pathogenic H5 avian influenza viruses in chickens immunized with a recombinant fowlpox vaccine containing an H5 avian influenza hemagglutinin gene insert," Vaccine (2000) 18:1088-1095.

Swayne, D.E., "Vaccines for List A poultry diseases: emphasis on avian influenza," Dev. Biol. (2003) 114:201-212.

Tang, M. et al., "Recombinant adenovirus encoding the HA gene from swine H3N2 influenza virus partially protects mice from challenge with heterologous virus: A/HK/1/68 (H3N2)," Arch. Virol. (2002) 147:2125-2141.

Webster et al., "Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage *P. falciparum* malaria in non-immune volunteers," Vaccine (2006) 24:3026-3034.

International Search Report and Written Opinion for Application No. PCT/US2008/082254 dated Jun. 17, 2009 (12 pages).

Examination Report for European Patent Application No. 08 843 740.5 dated Aug. 17, 2012 (6 pages).

First Office Action (translation of pertinent portions) for Chinese Patent Application No. 200880116875.0 (3 pages).

Extended European Search Report for European Patent Application No. 08843740.5 dated May 3, 2011 (15 pages).

Agterberg, M. et al., "Outer membrane protein PhoE as a carrier for the exposure of foreign antigenic determinants at the bacterial cell surface," Antoine Van Leeuwenhoek (1991) 59(4):249-262.

Barr, T.A. et al., "A potent adjuvant effect of CD40 antibody attached to antigen," Immunology (2003) 109:87-92.

Blomfield, L.C. et al., "Allelic exchange in *Escherichia coli* using the *Bacillus subtilis* sacB gene and a temperature-sensitive pSC101 replicon," Mol Microbiol (1991) 509:1447-1457.

Charbit, A. et al., "Probing the topology of a bacterial membrane protein by genetic insertion of a foreign epitope; expression at the cell surface," EMBO J (1986) 5(11):3029-3037.

Charbit, A. et al., "Versatility of a vector for expressing foreign polypeptides at the surface of gram-negative bacteria," Gene (1988) 70(1):181-189.

Cole, K. et al., "Evaluation of a novel recombinant *Salmonella* vaccine vector for avian influenza," Poultry Science (2007) 86(Supp. 1):585-586.

Cox, M.M. et al., "Scarless and site-directed mutagenesis in *Salmonella enteritidis* chromosome," BMC Biotech. (2007) 7(59):10 pages.

Dan Forth, H.D. et al., "Genetically engineered antigen confers partial protection against avian coccidial parasites," (1989) Poultry Science 68:1643-1652.

Du, A. et al., "Efficacy of a DNA vaccine delivered in attenuated *Salmonella typhimurium* against *Eimeria tenella* infection in chickens," International Journal of Parasitology (2005) 35:777-785.

Farnell, M.B. et al., "Upregulation of oxidative burst and degranulation in chicken heterophils stimulated with probiotic bacteria," Poult. Sci. (2006) 85:1990-1906.

(56)

References Cited

OTHER PUBLICATIONS

- Fecteau, J.F. et al., "CD40 Stimulation of Human Peripheral B Lymphocytes: Distinct Response from Naïve and Memory Cells," *J Immunol* (2003) 171:4621-4629.
- Gares, S.L. et al., "Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks," *Clin. Vaccine Immunol.* (2006) 13:958-965.
- Gast, R.K. et al., "The relationship between the magnitude of the specific antibody response to experimental *Salmonella enteritidis* infection in laying hens and their production of contaminated eggs," *Avian Diseases* (2001) 45:425-431.
- Grangette, C. et al., "Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: Impact and strain viability and in vivo persistence," *Vaccine* (2002) 20:3304-3309.
- Grewal, I.S. et al., "CD40 and CD154 in cell-mediated immunity," *Annu. Rev. Immunology*, (1998) 16:111-135.
- Harcourt, J.L. et al., "CD40 ligand (CD154) improves the durability of respiratory syncytial virus DNA vaccination in BALB/c mice," *Vaccine* (2003) 21(21-22):2964-2979.
- Hayes, L.J. et al., "*Chlamydia trachomatis* major outer membrane protein epitopes expressed as fusions with LamB in an attenuated *aroA* Strain of *Salmonella typhimurium*; their application as potential immunogens," *J. of General Microbiology* (1991) 137:1557-1564.
- Holmgren, J. et al., "Mucosal immunity: implications for vaccine development," *Immunobiol.* (1992). 184:157-179.
- Hussein, M.L. et al., "Rapid method for the construction of *Salmonella enterica* serovar typhimurium vaccine carrier strains," *Infect. Immun.* (2005) 73(3):1598-1605.
- Jenkins, M.C., "Progress on developing a recombinant coccidiosis vaccine," *International J. of Parasitology* (1998) 28:1111-1119.
- Koch, F. et al., "High level IL-12 production by marine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10," *J. Exp. Med.* (1996) 184:741-746.
- Konjufca, V. et al., "A recombinant attenuated *Salmonella enterica* serovar Typhimurium vaccine encoding *Eimeria acervulina* antigen offers protection against *E. acervulina* challenge," *Infection and Immunity* (2006) 74:6785-6796.
- Kotton, C.N. et al., "Enteric pathogens as vaccine vectors for foreign antigen delivery," *Infect. Immun.* (2004) 72:5535-5547.
- Kwon, Y.M. et al., "*Salmonella*-based vaccines for infectious diseases," *Expert Review of Vaccines* (2007) 6(2):147-152.
- Lapalombella, R. et al., "A Novel Raji-Burkitt's Lymphoma Model for Preclinical and Mechanistic Evaluation of CD52-Targeted Immunotherapeutic Agents," *Clin. Cancer Res.* (2008) 14:569-578.
- Lee, J.S. et al., "Surface-displayed viral antigens on *Salmonella* carrier vaccine," *Nat. Biotechnol.* (2000) 18:645-648.
- Li, W., "Synergistic antibody induction by antigen-CD40 ligand fusion protein as improved immunogen," *Immunology* (2005) 115(2):215-222.
- Lowe, D.C. et al., "Characterization of candidate live oral *Salmonella typhi* vaccine strains harboring defined mutations in *aroA*, *aroC*, and *htrA*," *Infection and Immunity* Feb. 1999:700-707.
- Miga, A. et al., "The role of CD40-CD154 interactions in the regulation of cell mediated immunity," *Immunol. Invest.* (2000) 29:111-114.
- O'Callaghan, D. et al., "Immunogenicity of foreign peptide epitopes expressed in bacterial envelope proteins," *Research in Microbiology* (1990) 141:963-969.
- Pasetti, M. et al., "Animal models paving the way for clinical trials of attenuated *Salmonella enterica* serovar Typhi live oral vaccines and live vectors," *Vaccine* (2003) 21:401-418.
- Pogonka, T. et al., "A single dose of recombinant *Salmonella typhimurium* induces specific humoral immune responses against heterologous *Eimeria tenella* antigens in chicken," *International Journal of Parasitology* (2003) 33:81-88.
- Rabsch, W. et al., "Competitive exclusion of *Salmonella enteritidis* by *Salmonella gallinarum* in poultry," *Emerging Inf. Diseases* (2000) 6(5):443-448.
- Russmann, H. et al., "Delivery of epitopes by the *Salmonella* type III secretion system for vaccine development," *Science* (1998) 281(5376):565-568.
- Schneider, J. et al., "A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the *Plasmodium falciparum* TRAP antigen in chimpanzees," *Vaccine* (2001) 19(32):4595-4602.
- Smith, et al., "Maternal transmission of immunity to *Eimeria maxima*: western blot analysis of protective antibodies induced by infection," *Infect. Immun.* (1994) 62:1348-1357.
- Su, G.F. et al., "Construction of stable LamB-Shiga toxin B subunit hybrids: analysis of expression in *Salmonella typhimurium aroA* strains and stimulation of B subunit-specific mucosal and serum antibody responses," *Infect Immun* (1992) 60(8):3345-3359.
- Tresgaskes, C.A. et al., "Conservation of biological properties of the CD40 ligand, CD154 in a non-mammalian vertebrate," *Dev. Comp. Immunol.* (2005) 29:361-374.
- Vega, M.L. et al., "A *Salmonella typhi* OmpC fusion protein expressing the CD154 Trp140-Ser149 amino acid strand binds CD40 and activates a lymphoma B-cell line," *Immunol.* (2003) 110:206-216.
- Verjans, G.M. et al., "Intracellular processing and presentation of T cell epitopes, expressed by recombinant *Escherichia coli* and *Salmonella typhimurium*, to human T cells," *Eur J Immunol* (1995) 25(2):405-410.
- Vermeulen, A.N., "Progress in recombinant vaccine development against coccidiosis a review and prospects into the next millennium," *International Journal of Parasitology* (1998) 28:1121-1130.
- Vierira-Pinto, M. et al., "Occurrence of *Salmonella* in the ileum, ileocolic lymph nodes, tonsils, mandibular lymph nodes and carcasses of pigs slaughtered for consumption," *J Vet Med B Infection Dis Vet Public Health* (2005) 52(10):476-481.
- Wallach, M. et al., "Maternal immunization with gametocyte antigens as a means of providing protective immunity against *Eimeria maxima* in chickens," *Infection and Immunity*, (1992) 60(5):2036-2039.
- Wang, J. et al., "Immunogenicity of viral B-cell epitopes inserted into two surface loops of the *Escherichia coli* K12 LamB protein and expressed in an attenuated *aroA* strain of *Salmonella typhimurium*," *Vaccine* (1999) 17(1):1-12.
- Witcombe, D.M. et al., "*Eimeria maxima* TRAP family protein EmTFP250: subcellular localisation and induction of immune responses by immunization with a recombinant C-terminal derivative," *Int. Jour. Parasitology* (2004) 34(7):861-872; abstract, p. 862 fig 1.
- Witcombe, D.M. et al., "Molecular characterisation of EmTFP250: A novel member of the TRAP protein family in *Eimeria maxima*," *International Journal of Parasitology* (2003) 33(7):691-702.
- Xu, Y. et al., "The role of CD40-CD154 interaction in cell immunoregulation," *J. Biomed. Sci.* (2004) 11:426-438.
- McConkey, S.J. et al., "Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans," (2003) *Nature Medicine* 9(6):729-735.
- Nakajima, A. et al., "Antitumor effect of CD40 ligand: Elicitation of local and systemic antitumor responses by IL-12 and B7," (1998) *Journal of Immunology* 161:1901-1907.
- Ochoa-Reparaz, J. et al., "Humoral immune response in hens naturally infected with *Salmonella enteritidis* against outer membrane proteins and other surface structural antigens," (2004) *Vet. Res.* 35:291-298.
- Patarroyo, M. et al., "Induction of protective immunity against experimental infection with malaria using synthetic peptides," (1987) *Nature* 328(6131):629-632.
- Manoj, S. et al., "Targeting with Bovine CD154 enhances humoral immune responses induced by a DNA vaccine in sheep," (2003) *Journal of Immunology* 170:989-996.
- Nakajima, A. et al., "Antitumor effect of CD40 ligand: Elicitation of local and systemic antitumor responses by IL-12 and B7," (1998) *Journal of Immunology* 161:1901-1907.
- Ochoa-Reparaz, J. et al., "Humoral immune response in hens naturally infected with *Salmonella enteritidis* against outer membrane proteins and other surface structural antigens," (2004) *Vet. Res.* 35:291-298.

* cited by examiner




FIG. 1


**PCR-A**

FIG. 2A


**PCR-B**

FIG. 2B

Mortality at 5 days post-challenge of broiler chickens challenged at 21 days of age with 10^4 /bird of sporulated oocyst of *E. maxima*.




Figure 3: In this experiment, day-of-hatch chicks were either not vaccinated (control) or vaccinated with the *Salmonella* vector expressing Sequence 1, 2, or 3 from the *Eimeria maxima* TRAP protein as described in the appendix. All chicks were challenged with exactly the same dose of *Eimeria maxima* at day 21. Necropsy confirmed that all mortality was related to *Eimeria maxima* infection. Mortality was markedly and significantly reduced in the group vaccinated with the vector expressing sequence 2.

1

COMPOSITIONS AND METHODS OF ENHANCING IMMUNE RESPONSES TO *EIMERIA*

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a national stage filing under 35 U.S.C. 371 of International Application No. PCT/US2008/082254, filed Nov. 3, 2008, which claims priority to U.S. Provisional Application Ser. No. 60/984,612, filed Nov. 1, 2007, both of which are incorporated herein by reference in their entirety.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

None.

INTRODUCTION

Coccidiosis, an infectious disease of poultry, swine, and cattle caused by the Apicomplexan protozoal parasite *Eimeria*, presents problems worldwide. Coccidiosis is among the top ten infectious diseases of poultry in terms of its economic impact on the poultry industry. Other members of the Apicomplexan family also cause disease, including *Plasmodium*, *Cryptosporidium* and *Toxoplasma* which are the causative agents of malaria, cryptosporidiosis and toxoplasmosis, respectively. The vaccines currently available against *Eimeria* are based on controlled low dosage of essentially fully virulent but drug-sensitive *Eimeria* parasites. Vaccination with current *Eimeria*-based vaccines produces substantial vaccine-reaction morbidity and economic losses in vaccinated flocks. Thus an effective low-virulence vaccine against *Eimeria* is needed. An effective vaccine for *Eimeria* may also prove useful as a vaccine against other Apicomplexan parasites.

SUMMARY

A vaccine comprising a first polynucleotide sequence encoding a TRAP polypeptide or an immunogenic fragment thereof is disclosed. The TRAP polypeptide may comprise SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, or an immunogenic fragment thereof. The vaccines optionally further include a second polynucleotide sequence encoding a CD154 polypeptide capable of binding CD40. The CD154 polypeptides include fewer than 50 amino acids and comprise amino acids 140-149, or a homolog thereof.

Vaccines according to the present invention may be comprised within a vector, such as a virus, bacterium, or liposome. In one aspect, a vaccine comprising a *Salmonella enteritidis* comprising a first polynucleotide sequence encoding a TRAP polypeptide is provided.

In still another aspect, the invention includes methods of enhancing the immune response against an Apicomplexan parasite in a subject by administering a vaccine according to the present invention.

In a still further aspect, the invention includes methods of reducing morbidity associated with infection with an Apicomplexan parasite in a subject by administering a vaccine according to the present invention.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 depicts the scheme for making site-directed mutations in *Salmonella enteritidis*.

2

FIG. 2 depicts the design scheme of the overlapping extension PCR method used to generate the TRAP and TRAP-CD 154 insertions into loop 9 of the lamB polynucleotide.

FIG. 3 is a bar graph showing the percent mortality at five days post-infection with *Eimeria maxima* after inoculation with a *Salmonella* vector expressing the indicated *Eimeria* TRAP sequence.

DETAILED DESCRIPTION

Recombinant DNA technologies enable relatively easy manipulation of many bacterial and viral species. Some bacteria and viruses are mildly pathogenic or non-pathogenic, but are capable of generating a robust immune response. These bacteria and viruses make attractive vaccines for eliciting an immune response to antigens. Bacterial or viral vaccines may mimic a natural infection and produce robust and long lasting mucosal immunity. Vaccines are often relatively inexpensive to produce and administer. In addition, such vectors can often carry more than one antigen and may provide protection against multiple infectious agents.

In one aspect, a vaccine comprising a first polynucleotide sequence encoding a TRAP polypeptide or an immunogenic fragment thereof is provided. The TRAP polypeptide may comprise SEQ ID NO:11 or an immunogenic fragment of SEQ ID NO:11. A vaccine includes any composition comprising a polynucleotide encoding an antigenic polypeptide that is capable of eliciting an immune response to the polypeptide. In another aspect, the use of vectors, such as bacterial vectors, for vaccination and generation of immune responses against *Eimeria* or other Apicomplexan parasites such as *Plasmodium* (the causative agent of malaria), *Toxoplasma* and *Cryptosporidium* is disclosed. *Salmonella* strains make suitable vectors because bacterial genes may be mutated or attenuated to create bacteria with low to no pathogenesis to the infected or immunized subject, while maintaining immunogenicity.

A high molecular mass, asexual stage antigen from *Eimeria maxima* (EmTFP250) was demonstrated to be a target for maternal antibodies produced by breeding hens infected with this protozoan parasite. Analysis of the amino acid sequence of the antigen revealed a novel member of the TRAP (thrombospondin-related anonymous protein) family, containing 16 thrombospondin type-1 repeats and 31 epidermal growth factor-like calcium binding domains. EmTFP250 or TRAP also contains two low complex, hydrophilic regions rich in glutamic acid and glycine residues, and a transmembrane domain cytosolic tail associated with parasite gliding motility that is highly conserved within apicomplexan microneme proteins. Several potential epitopes were selected and are identified in SEQ ID NO:1-3 and 11. Due to the conserved nature of this antigen, expression of these epitopes by a vector may induce protective immunity against multiple Apicomplexan parasites.

Salmonella may provide a useful vector because it can survive the gastrointestinal tract of the host and give rise to a mucosal immune response. Oral vaccines using a *Salmonella* vector produce a robust mucosal immune response and are relatively easy to administer to both animals and humans. However, many of the current *Salmonella* vaccine strains are not as effective in generating a strong protective immune response as compared to their more virulent counterparts. Virulent strains provide a robust immune response but may also cause significant morbidity to the vaccinated subject. A *Salmonella* strain that could be used for effective mucosal, e.g., oral, vaccination would provide a vector that could be

used to readily vaccinate a subject against one or more pathogenic agents, such as Apicomplexan parasites.

A *Salmonella enteritidis* strain useful as a vector, and various recombinant vectors made using this strain, are described. Specifically, a *Salmonella enteritidis* 13A (SE13A) capable of expressing an exogenous TRAP polypeptide is provided. In addition, a vaccine and methods of enhancing an immune response in a subject by administering the vaccine comprising a TRAP polynucleotide sequence encoding a TRAP polypeptide and a CD154 polynucleotide sequence encoding a polypeptide of CD154 or a homolog thereof that is capable of binding to CD40 are disclosed. The vaccines may be used to enhance an immune response against *Eimeria* or another Apicomplexan parasite, such as *Plasmodium*, *Toxoplasma* or *Cryptosporidium*, or may be used to reduce the morbidity associated with an infection caused by an Apicomplexan parasite.

A wild-type isolate of *Salmonella*, *Salmonella enteritidis* 13A (SE13A) (deposited with the American Type Culture Collection (ATCC) on Sep. 13, 2006, deposit number PTA-7871), was selected based upon its unusual ability to cause mucosal colonization and sub-mucosal translocation in chickens, permitting robust presentation of associated antigens or epitopes in commercial chickens. Importantly, this wild-type *Salmonella* isolate causes no clinically detectable disease or loss of performance in commercial chickens, indicating little disease-causing potential of the wild-type *Salmonella* in vertebrate animals.

The SE13A isolate may be further attenuated by inactivating at least one gene necessary for sustained replication of the bacteria outside of laboratory or manufacturing conditions. Attenuated or variant *Salmonella* strains that can be used as vectors are described below. SE13A was used to generate attenuated *Salmonella* strains to develop vaccines and generate enhanced immune responses. SE13A is invasive, non-pathogenic for poultry and causes no measurable morbidity. These features result in an enhanced immune response as compared to non-invasive bacterial vectors. Attenuation of SE13A by mutation of genes that limit the ability of the bacterium to spread may increase the safety of the vaccine. SE13A strains with mutations in *aroA* or *htrA* retain the ability to generate an immune response, but have limited replication in the host. Thus, the attenuation increases the safety of the vector without compromising the immunogenicity.

Mutations may be made in a variety of other *Salmonella* genes including, but not limited to, *cya*, *crp*, *asd*, *cdt*, *phoP*, *phoQ*, *ompR*, outer membrane proteins, *dam*, *htrA* or other stress related genes, *aro*, *pur* and *gua*. As shown in the Examples, mutations in *aroA* and *htrA* were found to attenuate SE13A. The *aro* genes are enzymes involved in the shikimate biosynthesis pathway or the aromatase pathway and *aro* mutants are auxotrophic for the aromatic amino acids tryptophan, tyrosine and phenylalanine. *htrA* is a stress response gene that encodes a periplasmic protease that degrades aberrant proteins. Mutants in *htrA* are also attenuated and display increased sensitivity to hydrogen peroxide.

The mutations in *aroA* and *htrA* described in the Examples are deletion mutations, but the mutations can be made in a variety of ways. Suitably, the mutations are non-reverting mutations that cannot be repaired in a single step. Suitable mutations include deletions, inversions, insertions and substitutions. A vector may include more than one mutation, for example a vector may contain mutations in both *aroA* and *htrA*. Methods of making such mutations are well known in the art.

Polynucleotides encoding TRAP polypeptide antigens and other antigens from any number of pathogenic organisms may be inserted into the vector (e.g., SE13A) and expressed by the bacteria. The expression of these polynucleotides by the vector will allow generation of antigenic polypeptides following immunization of the subject. The polynucleotides may be inserted into the chromosome of the bacteria or encoded on plasmids or other extrachromosomal DNA. Those of skill in the art will appreciate that numerous methodologies exist for obtaining expression of polynucleotides in vectors such as *Salmonella*. The polynucleotides may be operably connected to a promoter (e.g., a constitutive promoter, an inducible promoter, etc.) by methods known to those of skill in the art. Suitably, polynucleotides encoding TRAP antigens are inserted into a bacterial polynucleotide that is expressed. Suitably, the bacterial polynucleotide encodes a transmembrane protein, and the polynucleotide encoding the TRAP antigen is inserted into the bacterial polynucleotide sequence to allow expression of the TRAP antigen on the surface of the bacteria. For example, the polynucleotide encoding TRAP may be inserted in frame into the bacterial polynucleotide in a region encoding an external loop region of a transmembrane protein such that the bacterial polynucleotide sequence remains in frame. See Example 1.

Alternatively, the first polynucleotide encoding TRAP antigen may be inserted into a polynucleotide encoding a secreted polypeptide. Those of skill in the art will appreciate that the polynucleotide encoding the TRAP antigen could be inserted in a wide variety of bacterial polynucleotides to provide expression and presentation of the TRAP antigen to the immune cells of a subject treated with the vaccine. In the Examples, a first polynucleotide encoding the TRAP polypeptide was inserted into loop 9 of the *lamB* gene of SE13A. The polynucleotide encoding the TRAP antigen may be included in a single copy or more than one copy. A bacterial vector containing multiple copies of the TRAP antigen inserted into loop 9 of *lamB* may also be generated. Alternatively, multiple copies of an epitope may be inserted into the bacterial vector at more than one location.

Suitably the first polynucleotide encodes a portion of the TRAP polypeptide or the entire TRAP polypeptide. The polynucleotide may be inserted into the vector. In the Examples, three polypeptides (SEQ ID NO:1-3) were incorporated into SE13A. Suitably, the portion of the TRAP polypeptide inserted into the vector is an immunogenic fragment. An immunogenic fragment is a peptide or polypeptide capable of eliciting a cellular or humoral immune response. Suitably, an immunogenic fragment of TRAP may be 6 or more consecutive amino acids, 10 or more amino acids, 15 or more amino acids or 20 or more amino acids of the full-length protein sequence.

Other suitable epitopes for inclusion in a vaccine having TRAP comprised within a vector include, but are not limited to, polynucleotides encoding other *Eimeria*-related polypeptides. One of skill in the art will appreciate that a variety of sequences may be used in combination with any other antigen and may also be used in conjunction with polypeptides encoding immune stimulatory peptides such as a polypeptide of CD 154.

As described in more detail below, a vaccine including a vector may include a CD 154 polypeptide that is capable of binding CD40 in the subject and stimulating the subject to respond to the vector and its associated antigen. Involvement of dendritic cells (DCs) is essential for the initiation of a powerful immune response as they possess the unique ability to activate naïve T cells, causing T cell expansion and differentiation into effector cells. It is the role of the DC, which is

an antigen presenting cell (APC) found in virtually all tissues of the body, to capture antigens, transport them to associated lymphoid tissue, and then present them to naïve T cells. Upon activation by DCs, T cells expand, differentiate into effector cells, leave the secondary immune organs, and enter peripheral tissues. Activated cytotoxic T cells (CTLs) are able to destroy virus-infected cells, tumor cells or even APCs infected with intracellular parasites (e.g., *Salmonella*) and have been shown to be critical in the protection against viral infection. CD40 is a member of the TNF-receptor family of molecules and is expressed on a variety of cell types, including professional antigen-presenting cells (APCs), such as DCs and B cells. Interaction of CD40 with its ligand CD 154 is extremely important and stimulatory for both humoral and cellular immunity. Stimulation of DCs via CD40, expressed on the surface of DCs, can be simulated by anti-CD40 antibodies. In the body, however, this occurs by interaction with the natural ligand for CD40 (i.e. CD154) expressed on the surface of activated T-cells. Interestingly, the CD40-binding regions of CD154 have been identified. The CD40-binding region of CD 154 may be expressed on the surface of a vector, such as a *Salmonella* vector, and results in an enhanced immune response against a co-presented peptide sequence.

As described above, polynucleotides encoding CD154 polypeptides may be inserted into the chromosome of the vector or maintained extrachromosomally. A CD 154 polypeptide may be a portion of CD154 full-length protein or the entire CD154 protein. Suitably, the CD154 polypeptide is capable of binding CD40. One of skill in the art will appreciate that these polynucleotides can be inserted in frame in a variety of polynucleotides and expressed in different parts of the vector or may be secreted. The polynucleotide encoding a CD 154 polypeptide capable of enhancing the immune response to TRAP may also encode the TRAP antigen. The polynucleotide encoding a CD154 polypeptide may be linked to the polynucleotide encoding the TRAP antigen, such that in the vector, the CD 154 polypeptide and the TRAP antigen are present on the same polypeptide. In the Examples, a polynucleotide encoding a polypeptide of CD154 that is capable of binding to CD40 also encodes the TRAP antigen. See SEQ ID NOS: 1, 2, 3 and 11 in the attached sequence listing. In the Examples, the polynucleotides (SEQ ID NO:13-15) encoding the TRAP antigen and the polynucleotide encoding the CD154 polypeptide are both inserted in loop 9 of the lamB gene. Those of skill in the art will appreciate that bacterial polynucleotides encoding other transmembrane proteins and other loops of the lamB gene may also be used.

As discussed above, a CD 154 polynucleotide encoding a CD154 polypeptide that is capable of enhancing the immune response to the antigen may be included in the vaccine. Suitably, the CD 154 polypeptide is fewer than 50 amino acids long, more suitably fewer than 40, fewer than 30 or fewer than 20 amino acids in length. The polypeptide may be between 10 and 15 amino acids, between 10 and 20 amino acids or between 10 and 25 amino acids in length. The CD 154 sequence and CD40 binding region are not highly conserved among the various species. The CD154 sequences of chicken and human are provided in SEQ ID NO:10 and SEQ ID NO:4, respectively.

The CD40 binding regions of CD154 have been determined for a number of species, including human, chicken, duck, mouse and cattle and are shown in SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9, respectively. Although there is variability in the sequences in the CD40 binding region between species, the human CD 154 polypeptide was able to enhance the immune response in

chickens. Therefore, one may practice the invention using species specific CD 154 polypeptides or a heterologous CD 154 polypeptide.

In the Examples, several SE13A recombinant bacteria were generated. In each of the SE13A strains containing both the TRAP and CD154 polynucleotides, the TRAP polypeptide and the CD154 polypeptide were encoded on the same polynucleotide and were in frame with each other and with the *Salmonella* lamB polynucleotide in which they were inserted. In alternative embodiments, the CD 154 polypeptide and the TRAP polypeptide may be encoded by distinct polynucleotides. SE13A aroA htrA TRAP contains a deletion in aroA and htrA and encodes both the TRAP epitope (SEQ ID NO:1-3) and optionally the CD154 polypeptide (SEQ ID NO:4) inserted into loop 9 of lamB.

Compositions comprising an attenuated *Salmonella* strain and a pharmaceutically acceptable carrier are also provided. A pharmaceutically acceptable carrier is any carrier suitable for in vivo administration. Examples of pharmaceutically acceptable carriers suitable for use in the composition include, but are not limited to, water, buffered solutions, glucose solutions or bacterial culture fluids. Additional components of the compositions may suitably include, for example, excipients such as stabilizers, preservatives, diluents, emulsifiers and lubricants. Examples of pharmaceutically acceptable carriers or diluents include stabilizers such as carbohydrates (e.g., sorbitol, mannitol, starch, sucrose, glucose, dextran), proteins such as albumin or casein, protein-containing agents such as bovine serum or skimmed milk and buffers (e.g., phosphate buffer). Especially when such stabilizers are added to the compositions, the composition is suitable for freeze-drying or spray-drying.

Methods of enhancing immune responses in a subject by administering a vaccine containing a TRAP polypeptide and a CD 154 polypeptide capable of binding to CD40 and activating CD40 are also provided. The vaccine comprising the polynucleotide encoding a CD154 polypeptide capable of binding to CD40 is administered to a subject in an amount effective to enhance the immune response of the subject to the vaccine. Suitably, the vaccine contains a polynucleotide encoding a polypeptide including amino acids 140-149 of the human CD 154 polypeptide (SEQ ID NO:4) or a homolog thereof. Therefore, a homologue of amino acid 140-149 derived from one species may be used to stimulate an immune response in a distinct species.

Several suitable polypeptides are identified herein. Suitably, the polynucleotide encodes a CD154 polypeptide from the same species as the subject. Suitably, a polynucleotide encoding the polypeptide of SEQ ID NO:5 is used in human subjects, a polynucleotide encoding the polypeptide of SEQ ID NO:6 is used in chickens, a polynucleotide encoding the polypeptide of SEQ ID NO:7 is used in ducks, a polynucleotide encoding the polypeptide of SEQ ID NO:8 is used in mice, and a polynucleotide encoding the polypeptide of SEQ ID NO:9 is used in cows. In the Examples, the human CD154 polypeptide (SEQ ID NO:5) was used in a chicken vaccine and was demonstrated to enhance the immune response to a foreign antigen. Thus other heterologous combinations of CD 154 polypeptides and subjects may be useful in the methods of the invention. The CD154 polypeptide may be used to enhance the immune response in the subject to any foreign antigen or antigenic polypeptide present in the vaccine in addition to the TRAP polypeptide. One of skill in the art will appreciate that the CD 154 polypeptide could be used to enhance the immune response to more than one antigenic polypeptide present in a vaccine.

The polypeptide from CD154 stimulates an immune response at least in part by binding to its receptor, CD40. The Examples used a polypeptide homologous to the CD 154 polypeptide which is expressed on immune cells of the subject and which is capable of binding to the CD40 receptor on macrophages and other antigen presenting cells. Binding of this ligand-receptor complex stimulates macrophage (and macrophage lineage cells such as dendritic cells) to enhance phagocytosis and antigen presentation while increasing cytokine secretions known to activate other local immune cells (such as B-lymphocytes). As such, molecules associated with the CD154 peptide are preferentially targeted for immune response and expanded antibody production.

Potential vectors for use in the methods include, but are not limited to, *Salmonella* (*Salmonella enteritidis*), *Shigella*, *Escherichia* (*E. coli*), *Yersinia*, *Bordetella*, *Lactococcus*, *Lactobacillus*, *Bacillus*, *Streptococcus*, *Vibrio* (*Vibrio cholerae*), *Listeria*, adenovirus, poxvirus, herpesvirus, alphavirus, and adeno-associated virus.

In addition, methods of enhancing an immune response against an Apicomplexan parasite and methods of reducing morbidity associated with subsequent infection with an Apicomplexan parasite are disclosed. Briefly, the methods comprise administering to a subject a vaccine comprising a first polynucleotide sequence encoding a TRAP polypeptide in an effective amount. The TRAP polypeptides may include SEQ ID NO:1-3 and 11. The insertion of the TRAP polypeptides into the vector may be accomplished in a variety of ways known to those of skill in the art, including but not limited to the scarless site-directed mutation system described in BMC Biotechnol. 2007 September, 17: 7(1): 59, Scarless and Site-directed Mutagenesis in *Salmonella enteritidis* chromosome, which is incorporated herein by reference in its entirety. The vector may also be engineered to express the TRAP polypeptides in conjunction with other polypeptides capable of enhancing the immune response as discussed above, such as in SEQ ID NO:4 and SEQ ID NO:10. In particular, a polypeptide of CD154 capable of binding CD40 may be expressed by the vector to enhance the immune response of the subject to the TRAP polypeptide. Optionally, the vector is a bacterium, such as *Salmonella enteritidis*.

The useful dosage of the vaccine to be administered will vary depending on the age, weight and species of the subject, the mode and route of administration and the type of pathogen against which an immune response is sought. The composition may be administered in any dose sufficient to evoke an immune response. For bacterial vaccines, it is envisioned that doses ranging from 10^3 to 10^{10} bacteria, from 10^4 to 10^9 bacteria, or from 10^5 to 10^7 bacteria are suitable. The composition may be administered only once or may be administered two or more times to increase the immune response. For example, the composition may be administered two or more times separated by one week, two weeks, or by three or more weeks. The bacteria are suitably viable prior to administration, but in some embodiments the bacteria may be killed prior to administration. In some embodiments, the bacteria may be able to replicate in the subject, while in other embodiments the bacteria may not be capable of replicating in the subject.

For administration to animals or humans, the compositions may be administered by a variety of means including, but not limited to, intranasally, mucosally, by spraying, intradermally, parenterally, subcutaneously, orally, by aerosol or

intramuscularly. Eye-drop administration or addition to drinking water or food are additionally suitable. For chickens, the compositions may be administered in ovo.

Some embodiments of the invention provide methods of enhancing immune responses in a subject. Suitable subjects may include, but are not limited to, vertebrates, suitably mammals, suitably a human, and birds, suitably poultry such as chickens. Other animal models of infection may also be used. Enhancing an immune response includes, but is not limited to, inducing a therapeutic or prophylactic effect that is mediated by the immune system of the subject. Specifically, enhancing an immune response may include, but is not limited to, enhanced production of antibodies, enhanced class switching of antibody heavy chains, maturation of antigen presenting cells, stimulation of helper T cells, stimulation of cytolytic T cells or induction of T and B cell memory.

It is envisioned that several epitopes or antigens from the same or different pathogens may be administered in combination in a single vaccine to generate an enhanced immune response against multiple antigens. Recombinant vaccines may encode antigens from multiple pathogenic microorganisms, viruses or tumor associated antigens. Administration of vaccine capable of expressing multiple antigens has the advantage of inducing immunity against two or more diseases at the same time. For example, live attenuated bacteria, such as *Salmonella enteritidis* 13A, provide a suitable vector for eliciting an immune response against multiple antigens.

Bacterial vaccines may be constructed using exogenous polynucleotides encoding antigens which may be inserted into the bacterial genome at any non-essential site or alternatively may be carried on a plasmid using methods well known in the art. One suitable site for insertion of polynucleotides is within external portions of transmembrane proteins or coupled to sequences that target the exogenous polynucleotide for secretory pathways. One example of a suitable transmembrane protein for insertion of polynucleotides is the lamB gene. In the Examples, TRAP and CD 154 polynucleotides were inserted into loop 9 of the lamB sequence.

Exogenous polynucleotides include, but are not limited to, polynucleotides encoding antigens selected from pathogenic microorganisms or viruses and include polynucleotides that are expressed in such a way that an effective immune response is generated. Such polynucleotides may be derived from pathogenic viruses such as influenza (e.g., M2e, hemagglutinin, or neuraminidase), herpesviruses (e.g., the genes encoding the structural proteins of herpesviruses), retroviruses (e.g., the gp160 envelope protein), adenoviruses, paramyxoviruses, coronaviruses and the like. Exogenous polynucleotides can also be obtained from pathogenic bacteria, e.g., genes encoding bacterial proteins such as toxins, and outer membrane proteins. Further, exogenous polynucleotides from parasites, such as other Apicomplexan parasites are attractive candidates for use of a vector vaccine.

Polynucleotides encoding polypeptides involved in triggering the immune system may also be included in a vector, such as a live attenuated *Salmonella* vaccine. The polynucleotides may encode immune system molecules known for their stimulatory effects, such as an interleukin, Tumor Necrosis Factor, an interferon, or another polynucleotide involved in immune-regulation. The vaccine may also include polynucleotides encoding peptides known to stimulate an immune response, such as the CD 154 polypeptide described herein.

The following examples are meant only to be illustrative and are not meant as limitations on the scope of the invention or of the appended claims.

EXAMPLES

Example 1

Construction of TRAP and TRAP/CD154 Inserts

Strains and Culture Conditions

All plasmids were first maintained in TOP 10 *E. coli* cells (Invitrogen, Carlsbad, Calif., USA) unless described otherwise. *Salmonella enteritidis* 13A was used for introduction of mutations. *Salmonella enteritidis* strain 13A was a field isolate available from USDA/APHIS/NVSL and deposited with the ATCC as deposit number PTA-7871. Bacteria carrying plasmid pKD46 were grown at 30° C. Other bacteria were grown at 37° C. Plasmid curing was conducted at 37° C.

Luria-Bertani (LB) media was used for routine growth of cells, and SOC media (Invitrogen, Carlsbad, Calif., USA) was used for phenotypic expression after electroporation. When appropriate, the following antibiotics were added to the media: ampicillin (Amp) at 100 µg/ml, kanamycin (Km) at 50 µg/ml, and chloramphenicol (Cm) at 25 µg/ml.

Plasmids

Plasmids pKD46, pKD13, and pBC-1-SceI were described previously (Datsenko and Wanner, PNAS 2000, 97:6640-6645 and Kang et al., J Bacteriol 2004, 186:4921-4930, both of which are incorporated herein by reference in their entireties). Plasmid pKD46 encodes Red recombinase enzymes which mediate homologous recombination of incoming lin-

ear DNA with chromosomal DNA. This plasmid also contains the Ampicillin resistance gene and is temperature-sensitive so that it requires 30° C. for maintenance in the cell. Plasmid pKD13 served as a template for amplification of the Km resistance (Km^r) gene used in overlapping PCR. Plasmid pBC-1-SceI, which is maintained in the cell at 37° C., produces the I-SceI enzyme, which cleaves the following 18 base pair, rare recognition sequence: 5'-TAGGGATAACAGGG-TAAT-3' (SEQ ID NO:16). Plasmid pBC-1-SceI also contains the chloramphenicol resistance (Cm^r) gene.

PCR

All primers used for PCR are listed in Table 1. Typically, PCR was performed using approximately 0.1 µg of purified genomic, plasmid or PCR-generated DNA (Qiagen, Valencia, Calif., USA), 1× cloned Pfu polymerase buffer, 5U Pfu polymerase (Stratagene La Jolla, Calif., USA), 1 mM dNTPs (GE Healthcare Bio-Sciences Corp., Piscataway, N.J.), and 1.2 µM of each primer in a total volume of 50 µL. The DNA engine thermal cycler (Bio-Rad, Hercules, Calif., USA) was used with the following amplification conditions: 94° C. for 2 minutes; 30 cycles of 94° C. for 30 sec, 58° C. for 60 sec, 72° C. for 90 sec per 1 kb; and 72° C. for 10 minutes for final extension. Each PCR product was gel purified (Qiagen, Valencia, Calif., USA) and either eluted in 25 µL EB buffer for preparation of templates used in overlapping extension PCR or in 50 µL EB buffer, ethanol precipitated and suspended in 5 µL of ddH₂O for electroporation into *S. enteritidis*.

TABLE 1

Primer sequences		
Primer	Amplified region	Primer sequence
lam-up-f	loop 9 up	5' TGTACAAGTGGACGCCAATC 3' (SEQ ID NO: 17)
lam-up-r		5' GTTATCGCCGTCTTTGATATAGCC 3' (SEQ ID NO: 18)
lam-dn-f	loop 9 dn	5' ATTTCCCGTTATGCCGCAGC 3' (SEQ ID NO: 19)
lam-dn-r		5' GTTAACAGAGGGCGACGAG 3' (SEQ ID NO: 20)
Km-f	I-SceI/ Km ^r gene	5' GCTATATCAAAGACGGCGATAACTAATAACGGTCTCCTAAGGT
Km-r		AGCGAATTTCGGGGATCCGTCGA 3' (SEQ ID NO: 21)
		5' GCTCGGCATACCGGAAATTGTAGGCTGGAGCTGCTTCG 3' (SEQ ID NO: 22)
Kan4f	inside	5' CAAAGCGCTCTGAAGTTCC 3' (SEQ ID NO: 23)
Kan4r		5' GCGTGAGGGATCTTGAAGT 3' (SEQ ID NO: 24)
	Km ^r gene: sequencing	
SEQ1	SEQ1 hCD154/ loop 9 up	5' GGAGGACGCAACCGCCGCGTTCGGAAAACCAACCGGAGGA
hCD154 up reverse		GGAGTTATCGCCGTCTTTGATATAGCC 3' (SEQ ID NO: 25)
SEQ1hCD	SEQ1hCD154/ loop 9 down	5' CCGCGGCGGTTGCGTCCTCTCTGCGCAGAAAAGGTTATTAT
154 down forward		ACCATGTCTTCTCTCCATTTCCTCGTTATGCCGCGAGC 3' (SEQ ID NO: 26)
SEQ2	SEQ2-hCD154/ loop 9 up	5' TTTTCTTCTTCTTCTCCGGTTCGGACGTT
hCD154 up reverse		CATGACCTTCTTCGGCTTCGGCTGAACCGCCGG GGTTTCCGCGCGCGGAGGAGGTTATCGCCG TCTTTGATATAGCC 3' (SEQ ID NO: 27)
SEQ2	SEQ2-hCD154/ loop 9 down	5' ACCGGAAGAAGAAGAAAAAAGAAGAGGTGGTGGTTT
hCD154 up reverse		TCCGACCGCGCGGTTGCGTCCTCTCTGCGCAGAAAAGGTTA TTATACCATGTCTTCTCTCCATTTCCTGTTATGCCGCGAGC 3' (SEQ ID NO: 28)
SEQ3	SEQ3 hCD154/ loop 9 up	5' GCAACACCAACCAACCGCCGCGATCAGCAGAACCAACCA
Hcd154 up reverse		CACCAACCGCAACCGCCGCGTTCGGAAAACCAACCGGAGGAG GAGTTATCGCCGTCTTTGATATAGCC 3' (SEQ ID NO: 29)

TABLE 1-continued

Primer sequences		
Primer	Amplified region	Primer sequence
SEQ3 hCD154 up reverse	SEQ3-hCD154/ loop 9 down	5' GGC GGT GGTGGTGGTGGTGGCGGTTACCTCCGGTGGTGGTG GTGCGGGTGCAGGAATCCTCCTCCTGGGCAGAAAAAGTTAT TATACCATGTCTTCTCCTCCATTCCCGTTATGCCGAGC 3' (SEQ ID NO: 30)
lam 3f	outer regions	5' GCCATCTCGCTTGGTGATAA 3' (SEQ ID NO: 31)
lam 3r	of loop 9: sequencing	5' CGCTGGTATTTTGCGGTACA 3' (SEQ ID NO: 32)

In Table 1, italicized nucleotides are complementary to either side of the lamB gene loop 9 insertion site, which corresponds to nucleotide 1257 using *S. typhimurium* as an annotated reference genome. Bold font nucleotides represent the I-SceI recognition site in the Km-f primer.

Electroporation

Transformation of pKD46 into *S. enteritidis* was the first step carried out so that Red recombinase enzymes could be used for mediating recombination of subsequent mutations. Plasmid pKD46 was harvested from *E. coli* BW25113 (Datsenko and Wanner, PNAS 2000, 97:6640-6645) using a plasmid preparation kit (Qiagen Valencia, Calif., USA). Then 0.5 µL of pKD46 DNA was used for transformation into *S. enteritidis* 13A which had been prepared for electroporation. (Datsenko and Wanner, PNAS 2000, 97:6640-6645). Briefly, cells were inoculated into 10-15 mL of 2×YT broth and grown at 37° C. overnight. Then 100 µL of overnight culture was re-inoculated into 10 mL fresh 2×YT broth at 37° C. for 3-4 hours. Cells to be transformed with pKD46 plasmid were heated at 50° C. for 25 minutes to help inactivate host restriction. Cells were washed five times in ddH₂O water and resuspended in 60 µL of 10% glycerol. Cells were then pulsed at 2400-2450 kV for 1-6 ms, incubated in SOC for 2-3 hours at 30° C. and plated on LB media with appropriate antibiotics. *S. enteritidis* transformants with pKD46 were maintained at 30° C. When these transformants were prepared for additional electroporation reactions, all steps were the same except that 15% arabinose was added to induce Red recombinase enzymes one hour prior to washing, and cells did not undergo the 50° C. heat step.

Loop 9 up-I-SceI/Km^r-Loop 9 Down Construct

Introduction of I-SceI enzyme recognition site along with the Km^r gene into loop 9 of the lamB gene was done by combining the Red recombinase system (Datsenko and Wanner, PNAS 2000, 97:6640-6645, which is incorporated herein by reference in its entirety) and overlapping PCR (Horton et al., BioTechniques 1990, 8:528-535, which is incorporated herein by reference in its entirety). The insertion site corresponds to nucleotide 1257 of the lamB gene using *Salmonella typhimurium* LT2 (*S. typhimurium*) as an annotated reference genome. First, the upstream and downstream regions immediately flanking the loop 9 insertion site (loop 9 up and loop 9 down, respectively) were amplified separately. Primers used were lam-up-f and lam-up-r for loop 9 up and lam-dn-f and lam-dn-r for loop 9 down. Then the Km^r gene from pKD13 plasmid was amplified using primers Km-f and Km-r. Here, the I-SceI enzyme site was synthetically added to the 5' end of Km-f primer then preceded by a region complementary to the loop-up-r primer. Likewise, a region complementary to the loop-dn-f primer was added to the 5' end of Km-r primer. The complementary regions allow all 3 PCR products to anneal when used as templates in one PCR reaction. FIG. 2a repre-

sents this design scheme. PCR fragments consisting of loop 9 up-1-SceI/Km^r-loop 9 down sequence (PCR-A) were electroporated into *S. enteritidis* cells, which harbored pKD46 and were induced by arabinose, and then plated on LB with Km plates. To verify the correct sequence orientation of the mutation, we performed colony PCR with primer pairs Kan4F/lam3f and Kan4R/lam3r, where Kan4F and Kan4R are Km^r gene-specific primers and lam3f and lam3r are primers located outside the lamB loop 9 region. These PCR fragments were gel purified (Qiagen, Valencia, Calif., USA) and used for DNA sequencing.

Loop 9 up-TRAP-CD154-Loop 9 Down Construct

The final overlapping PCR fragment, PCR-B, contained the added TRAP antigen in combination with CD 154 sequences flanked by loop 9 up and down regions (FIG. 2b). Combination sequences consisted of TRAP polynucleotide encoding SEQ ID NO:1-3 and CD154 along with spacers such as Serine (Ser) residues.

To shorten the amount of steps for construction of the next fragment, the TRAP-CD154 sequence was synthetically added to the 5' end of the lam-dn-f primer and preceded by the complimentary region to the loop-up-r primer. The previously used PCR product for loop 9 up could be used together with the newly constructed PCR product in which the TRAP-CD154s were incorporated at the 5' end of loop 9 down to perform the final PCR reaction. However, for other insert sequences, an extra PCR step was needed, due to the longer lengths of insert sequences, to amplify loop 9 up with added nucleotides specific to insertion sequences connected to loop-up-r primer. The coding sequence for Gly (GGT) and Serine (TCC) as well as all other amino acids were chosen based on compiled data of the most frequently used codons in *E. coli* and *Salmonella typhimurium* proteins. See Table 1 for further details of primer design.

I-SceI Site/Km^r Insertion Mutation

The first mutation step involved designing a PCR fragment, PCR-A, which would serve as the carrier of the I-SceI site/Km^r cassette to be inserted into the lamB site. PCR-A consisted of the I-SceI enzyme recognition site adjacent to the Km^r gene with approximately 200-300 bp of flanking DNA on each end homologous to the upstream and downstream regions of lamB loop 9 insertion site (loop 9 up and loop 9 down, respectively). The fragment was introduced into *S. enteritidis* cells expressing Red recombinase enzymes and Km^r colonies were selected. After screening a few colonies by colony PCR, positive clones were sequenced for the desired inserted I-SceI site/Km^r sequence, and the identified mutant was selected and designated as SE 164.

Genomic Replacement of I-SceI/Km^r with TRAP-CD154s

The second mutation step required constructing a PCR fragment, referred to as PCR-B and shown in FIG. 2B, consisting of the final insertion sequence, the TRAP-CD 154s,

13

flanked by lamB homologous fragments. PCR-B amplicons have no selection marker and must be counter-selected after replacement for the previous I-SceI site/Km^r mutation in SE164. Plasmid pBC-I-SceI encodes the Cm^r gene and the I-SceI enzyme, which will cut the genome at the I-SceI site of SE164. Therefore, pBC-I-SceI was electroporated into SE164 along with PCR-B. After recombination of PCR-B to replace PCR-A, positive clones were chosen based on the ability to grow on Cm but not on Km. After DNA sequencing of mutants to confirm successful recombination of PCR-B, the strains were designated Sequence 1, Sequence 2 and Sequence 3. Ten random clones for each of the TRAP-CD154 insertions were used for PCR with lam 3f and lam 3r then digested using unique restriction enzymes sites for each insertion sequence and 100% of clones tested by digestion were positive for the desired mutation sequence. Sequencing results demonstrated that the insertion of TRAP-CD154 was exactly into the loop 9 region without the addition of extraneous nucleotides in each case. The inserts of the TRAP-CD154 vaccines are as follows: TRAP-CD154 (SEQ ID NO:33); TRAP-US-CD154 (SEQ ID NO:34); TRAP-DS-CD154 (SEQ ID NO:35).

Example 2

Attenuation of TRAP-CD154 Mutants/Inserts

Attenuation of SE13A was achieved by deletion mutation of the aroA gene and/or the htrA gene. Mutation of the aroA gene, a key gene in the chorismic acid pathway of bacteria, results in a severe metabolic deficiency which affects seven separate biochemical pathways. Mutation of the htrA gene reduces the cell's ability to withstand exposure to low and high temperatures, low pH, and oxidative and DNA damaging agents and reduces the bacteria's virulence.

To achieve deletion mutations in SE13A, the target gene sequence in the bacterial genome of *S. enteritidis* was replaced with the Km resistant gene sequence. This was completed using overlapping extension PCR and electroporation of the PCR products as described above. The Km resistance gene was targeted into the genomic region containing the genes of interest (aroA or htrA) by flanking the Km resistance gene with 200-300 base pairs of sequences homologous to the genes of interest. Once Km resistant mutants were obtained, the aroA and htrA deletion mutations were confirmed by DNA sequencing. Analogous aroA- and htrA-*Salmonella* strains were deposited with the American Type Culture Collection on Sep. 13, 2006 (Deposit No. PTA-7872 and Deposit No. PTA-7873, respectively). The attenuated strains were previously tested in vivo with regards to clearance time. Both of the attenuated strains had quicker clearance times than did the wildtype 13A strain, but both were able to colonize the liver, spleen, and cecal tonsils of chickens after oral infection.

14

Attenuated strains comprising the TRAP-CD154s and lacking both aroA and htrA were isolated.

Example 3

Protection of Chicks from Mortality after *Eimeria* Infection

Day-of-hatch chicks (n=280) were orally vaccinated with about 1×10⁸ cfu of the *Salmonella* isolates comprising the three distinct polynucleotides encoding the TRAP polypeptides of SEQ ID NO:1-3 or saline control. At 21 days of age, the chicks were orally challenged with 10⁴ sporulated oocysts of *Eimeria maxima*. The chicks were monitored daily post challenge. As depicted in FIG. 3, mortality of chicks at day 5 post challenge was reduced as compared to non-vaccinated animals irrespective of the vaccine strain given. The mortality was as follows: TRAP (SEQ ID NO:1) 7/43 (16.3%); TRAP US (SEQ ID NO:2) 1/46 (2.2%); TRAP DS (SEQ ID NO:3) 6/43 (11%); Control (unvaccinated) 10/46 (21.7%). Surprisingly, the chicks vaccinated with a *Salmonella* comprising TRAP polypeptide of SEQ ID NO:2 demonstrated marked and significantly reduced mortality as compared to control non-vaccinated chicks (P<0.001). Necropsy was performed and indicated that all mortality was related to the *Eimeria maxima* infection.

In a repeat experiment, mortality in the vaccinated bird (6/48) was significantly lower than the controls (17/50) and performance was better in the vaccinated chicks, but the difference was not significant.

In addition, serum was collected from immunized birds and an ELISA for TRAP performed. A robust TRAP specific antibody response was generated in the birds vaccinated with TRAP-US (SEQ ID NO:2).

Example 4

Morbidity Associated with Vaccination is Limited

To evaluate the efficacy of TRAP US-CD154 (SEQ ID NO:34) as a potential vaccine candidate, a similar study was completed to investigate morbidity associated with vaccination. Broiler chickens were orally vaccinated with 1×10⁸ cfu/bird of the *Salmonella* vaccine with TRAP US and CD154 insert (SEQ ID NO:34) or sham vaccinated with saline. Coccidia challenge was performed with sporulated oocytes of *Eimeria maxima* (10⁵ sporulated oocysts/bird) at three weeks post-vaccination. Body weight gain and lesions were evaluated 7 days post-challenge. Immunized birds showed a significant (p<0.01) improvement in performance. Immunized birds had about a 31% weight gain as compared to unvaccinated controls. Thus, vaccination with a *Salmonella*-based vaccine comprising a TRAP polypeptide and a CD154 polypeptide capable of binding CD40 may protect birds from morbidity and mortality associated with *Eimeria* infection.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 35

<210> SEQ ID NO 1
<211> LENGTH: 10
<212> TYPE: PRT
<213> ORGANISM: *Eimeria maxima*

<400> SEQUENCE: 1

Gly Gly Gly Phe Pro Thr Ala Ala Val Ala

-continued

1 5 10

<210> SEQ ID NO 2
 <211> LENGTH: 40
 <212> TYPE: PRT
 <213> ORGANISM: Eimeria maxima

<400> SEQUENCE: 2

Ala Ala Pro Glu Thr Pro Ala Val Gln Pro Lys Pro Glu Glu Gly His
 1 5 10 15

Glu Arg Pro Glu Pro Glu Glu Glu Glu Lys Lys Glu Glu Gly Gly
 20 25 30

Gly Phe Pro Thr Ala Ala Val Ala
 35 40

<210> SEQ ID NO 3
 <211> LENGTH: 40
 <212> TYPE: PRT
 <213> ORGANISM: Eimeria maxima

<400> SEQUENCE: 3

Gly Gly Gly Phe Pro Thr Ala Ala Val Ala Gly Gly Val Gly Gly Val
 1 5 10 15

Leu Leu Ile Ala Ala Val Gly Gly Gly Val Ala Ala Phe Thr Ser Gly
 20 25 30

Gly Gly Gly Ala Gly Ala Gln Glu
 35 40

<210> SEQ ID NO 4
 <211> LENGTH: 261
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 4

Met Ile Glu Thr Tyr Asn Gln Thr Ser Pro Arg Ser Ala Ala Thr Gly
 1 5 10 15

Leu Pro Ile Ser Met Lys Ile Phe Met Tyr Leu Leu Thr Val Phe Leu
 20 25 30

Ile Thr Gln Met Ile Gly Ser Ala Leu Phe Ala Val Tyr Leu His Arg
 35 40 45

Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val
 50 55 60

Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser
 65 70 75 80

Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys
 85 90 95

Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu
 100 105 110

Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser
 115 120 125

Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly
 130 135 140

Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln
 145 150 155 160

Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr
 165 170 175

Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser
 180 185 190

-continued

Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala
 195 200 205
 Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His
 210 215 220
 Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn
 225 230 235 240
 Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe
 245 250 255
 Gly Leu Leu Lys Leu
 260

<210> SEQ ID NO 5
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Homo sapiens

<400> SEQUENCE: 5

Trp Ala Glu Lys Gly Tyr Tyr Thr Met Ser Cys
 1 5 10

<210> SEQ ID NO 6
 <211> LENGTH: 11
 <212> TYPE: PRT
 <213> ORGANISM: Gallus gallus

<400> SEQUENCE: 6

Trp Met Thr Thr Ser Tyr Ala Pro Thr Ser Ser
 1 5 10

<210> SEQ ID NO 7
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Anas sp.

<400> SEQUENCE: 7

Trp Asn Lys Thr Ser Tyr Ala Pro Met Asn
 1 5 10

<210> SEQ ID NO 8
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Mus sp.

<400> SEQUENCE: 8

Trp Ala Lys Lys Gly Tyr Tyr Thr Met Lys
 1 5 10

<210> SEQ ID NO 9
 <211> LENGTH: 10
 <212> TYPE: PRT
 <213> ORGANISM: Bos taurus

<400> SEQUENCE: 9

Trp Ala Pro Lys Gly Tyr Tyr Thr Leu Ser
 1 5 10

<210> SEQ ID NO 10
 <211> LENGTH: 272
 <212> TYPE: PRT
 <213> ORGANISM: Gallus gallus

<400> SEQUENCE: 10

-continued

```

Met Asn Glu Ala Tyr Ser Pro Ala Ala Pro Arg Pro Met Gly Ser Thr
1      5      10      15

Ser Pro Ser Thr Met Lys Met Phe Met Cys Phe Leu Ser Val Phe Met
      20      25      30

Val Val Gln Thr Ile Gly Thr Val Leu Phe Cys Leu Tyr Leu His Met
      35      40      45

Lys Met Asp Lys Met Glu Glu Val Leu Ser Leu Asn Glu Asp Tyr Ile
50      55      60

Phe Leu Arg Lys Val Gln Lys Cys Gln Thr Gly Glu Asp Gln Lys Ser
65      70      75      80

Thr Leu Leu Asp Cys Glu Lys Val Leu Lys Gly Phe Gln Asp Leu Gln
      85      90      95

Cys Lys Asp Arg Thr Ala Ser Glu Glu Leu Pro Lys Phe Glu Met His
      100      105      110

Arg Gly His Glu His Pro His Leu Lys Ser Arg Asn Glu Thr Ser Val
      115      120      125

Ala Glu Glu Lys Arg Gln Pro Ile Ala Thr His Leu Ala Gly Val Lys
130      135      140

Ser Asn Thr Thr Val Arg Val Leu Lys Trp Met Thr Thr Ser Tyr Ala
145      150      155      160

Pro Thr Ser Ser Leu Ile Ser Tyr His Glu Gly Lys Leu Lys Val Glu
      165      170      175

Lys Ala Gly Leu Tyr Tyr Ile Tyr Ser Gln Val Ser Phe Cys Thr Lys
      180      185      190

Ala Ala Ala Ser Ala Pro Phe Thr Leu Tyr Ile Tyr Leu Tyr Leu Pro
195      200      205

Met Glu Glu Asp Arg Leu Leu Met Lys Gly Leu Asp Thr His Ser Thr
210      215      220

Ser Thr Ala Leu Cys Glu Leu Gln Ser Ile Arg Glu Gly Gly Val Phe
225      230      235      240

Glu Leu Arg Gln Gly Asp Met Val Phe Val Asn Val Thr Asp Ser Thr
      245      250      255

Ala Val Asn Val Asn Pro Gly Asn Thr Tyr Phe Gly Met Phe Lys Leu
260      265      270

```

```

<210> SEQ ID NO 11
<211> LENGTH: 70
<212> TYPE: PRT
<213> ORGANISM: Eimeria maxima

```

```

<400> SEQUENCE: 11

```

```

Ala Ala Pro Glu Thr Pro Ala Val Gln Pro Lys Pro Glu Glu Gly His
1      5      10      15

Glu Arg Pro Glu Pro Glu Glu Glu Glu Lys Lys Glu Glu Gly Gly
      20      25      30

Gly Phe Pro Thr Ala Ala Val Ala Gly Gly Val Gly Gly Val Leu Leu
      35      40      45

Ile Ala Ala Val Gly Gly Gly Val Ala Ala Phe Thr Ser Gly Gly Gly
50      55      60

Gly Ala Gly Ala Gln Glu
65      70

```

```

<210> SEQ ID NO 12
<211> LENGTH: 30
<212> TYPE: DNA
<213> ORGANISM: Eimeria maxima

```


-continued

<400> SEQUENCE: 12

ggtggtggtt ttccgaccgc ggcggttgcg 30

<210> SEQ ID NO 13

<211> LENGTH: 120

<212> TYPE: DNA

<213> ORGANISM: Eimeria maxima

<400> SEQUENCE: 13

gcggcgccgg aaaccccgcc ggttcagccg aaagccgaag aaggtcatga acgtccggaa 60

ccggaagaag aagaagaaaa aaaagaagaa ggtggtggtt ttccgaccgc ggcggttgcg 120

<210> SEQ ID NO 14

<211> LENGTH: 120

<212> TYPE: DNA

<213> ORGANISM: Eimeria maxima

<400> SEQUENCE: 14

ggtggtggtt ttccgaccgc ggcggttgcg ggtggtgttg gtggtgttct gctgatcgcg 60

gcggttggtg gtggtgttgc ggcgtttacc tccggtggtg gtggtgctggg tgcgcaggaa 120

<210> SEQ ID NO 15

<211> LENGTH: 210

<212> TYPE: DNA

<213> ORGANISM: Eimeria maxima

<400> SEQUENCE: 15

gcggcgccgg aaaccccgcc ggttcagccg aaagccgaag aaggtcatga acgtccggaa 60

ccggaagaag aagaagaaaa aaaagaagaa ggtggtggtt ttccgaccgc ggcggttgcg 120

ggtggtgttg gtggtgttct gctgatcgcg gcggttggtg gtggtgttgc ggcgtttacc 180

tccggtggtg gtggtgctggg tgcgcaggaa 210

<210> SEQ ID NO 16

<211> LENGTH: 18

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: I-SceI enzyme recognition sequence

<400> SEQUENCE: 16

tagggataac agggtaat 18

<210> SEQ ID NO 17

<211> LENGTH: 20

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: loop 9 up

<400> SEQUENCE: 17

tgtacaagtg gacgccaatc 20

<210> SEQ ID NO 18

<211> LENGTH: 24

<212> TYPE: DNA

<213> ORGANISM: Artificial Sequence

<220> FEATURE:

<223> OTHER INFORMATION: loop 9 up

<400> SEQUENCE: 18

-continued

 gttatcgccg tctttgatat agcc 24

<210> SEQ ID NO 19
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: loop 9 dn

<400> SEQUENCE: 19

atttcccgtt atgccgcagc 20

<210> SEQ ID NO 20
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: loop 9 dn

<400> SEQUENCE: 20

gttaaacaga gggcgacgag 20

<210> SEQ ID NO 21
 <211> LENGTH: 68
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: I-SceI/Kmr gene

<400> SEQUENCE: 21

gctatatcaa agacggcgat aactaactat aacggctccta aggtagcgaa tttccgggga 60

tccgtcga 68

<210> SEQ ID NO 22
 <211> LENGTH: 40
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: I-SceI/Kmr gene

<400> SEQUENCE: 22

gctgcggcat aacgggaaat tgtaggctgg agctgcttcg 40

<210> SEQ ID NO 23
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: inside Kmr gene: sequencing

<400> SEQUENCE: 23

caaaagcgct ctgaagttcc 20

<210> SEQ ID NO 24
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: inside Kmr gene: sequencing

<400> SEQUENCE: 24

gcgtgagggg atcttgaagt 20

<210> SEQ ID NO 25
 <211> LENGTH: 69

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: SEQ1 hCD154/ loop 9 up

<400> SEQUENCE: 25

ggagagcgca accgccgcgg tcggaaaacc accaccggag gaggagtat cgcggtcttt      60
gatatagcc                                           69

<210> SEQ ID NO 26
<211> LENGTH: 82
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: SEQ1hCD154/ loop 9 down

<400> SEQUENCE: 26

ccgcggcggt tgcgtctctc tcttgggcag aaaaagggtta ttataccatg tcttctctct      60
ccatttcccg ttatgccgca gc                                           82

<210> SEQ ID NO 27
<211> LENGTH: 113
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: SEQ2-hCD154/ loop 9 up

<400> SEQUENCE: 27

ttttcttctt cttcttcggt ttccggacgt tcatgacctt cttcggtttt cggtcgaacc      60
gccgggggttt ccggcgccgc ggaggaggag ttatcgccgt ctttgatata gcc          113

<210> SEQ ID NO 28
<211> LENGTH: 129
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: SEQ2-hCD154/ loop 9 down

<400> SEQUENCE: 28

accggaagaa gaagaagaaa aaaaagaaga aggtggtggt tttccgaccg cggcggttgc      60
gtcctctctc tgggcagaaa aaggttatta taccatgtct tctctctcca tttcccgta      120
tgccgcagc                                           129

<210> SEQ ID NO 29
<211> LENGTH: 113
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: SEQ3 hCD154/ loop 9 up

<400> SEQUENCE: 29

gcaacaccac caccaaccgc cgcgatcagc agaacaccac caacaccacc cgcaaccgcc      60
ggggtcggaa aaccaccacc ggaggaggag ttatcgccgt ctttgatata gcc          113

<210> SEQ ID NO 30
<211> LENGTH: 129
<212> TYPE: DNA
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: SEQ3-hCD154/ loop 9 down

<400> SEQUENCE: 30

```

-continued

ggcgggttggt ggtggtgttg cggcggtttac ctccggtggt ggtggtgcgg gtgcgcagga	60
atcctcctcc tgggcagaaa aagggttatta taccatgtct tctcctccca ttcccggtta	120
tgccgcagc	129

<210> SEQ ID NO 31
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: outer regions of loop 9: sequencing

<400> SEQUENCE: 31

gccatctcgc ttggtgataa	20
-----------------------	----

<210> SEQ ID NO 32
 <211> LENGTH: 20
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: outer regions of loop 9: sequencing

<400> SEQUENCE: 32

cgctgggtatt ttgcggtaca	20
------------------------	----

<210> SEQ ID NO 33
 <211> LENGTH: 87
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: TRAP-CD154

<400> SEQUENCE: 33

tcctcctccg gtggtggttt tccgaccgcg gcggttgctg cctcctcctg ggcagaaaaa	60
ggttattata ccatgtcttc ctctccc	87

<210> SEQ ID NO 34
 <211> LENGTH: 177
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: TRAP-US-CD154

<400> SEQUENCE: 34

tcctcctccg cggcgccgga aaccccgcg gttcagccga aagccgaaga aggtcatgaa	60
cgcccggaac cggaagaaga agaagaaaaa aaagaagaag gtggtggttt tccgaccgcg	120
gcggttgctg cctcctcctg ggcagaaaaa gggtattata ccatgtcttc ctctccc	177

<210> SEQ ID NO 35
 <211> LENGTH: 177
 <212> TYPE: DNA
 <213> ORGANISM: Artificial Sequence
 <220> FEATURE:
 <223> OTHER INFORMATION: TRAP-DS-CD154

<400> SEQUENCE: 35

tcctcctccg gtggtggttt tccgaccgcg gcggttgctg gtggtgttg tggtgttctg	60
ctgatcgcg cggttggttg tggtgttgcg gcgtttacct ccggtggttg tggtgcgggt	120
gcgcaggaat cctcctcctg ggcagaaaaa gggtattata ccatgtcttc ctctccc	177

29

We claim:

1. A vaccine comprising a vector comprising a first polynucleotide sequence encoding a thrombospondin-related anonymous protein (TRAP polypeptide), wherein the TRAP polypeptide sequence is selected from SEQ ID NO:1, SEQ ID NO:2 and SEQ ID NO:3 and a second polynucleotide sequence encoding a CD154 polypeptide capable of binding CD40, the CD154 polypeptide having fewer than 50 amino acids and comprising amino acids 140-149 of SEQ ID NO:4 or is selected from one of SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, and SEQ ID NO:9.

2. The vaccine of claim 1, wherein the TRAP polypeptide is SEQ ID NO:2.

3. The vaccine of claim 1, wherein the CD154 polypeptide is SEQ ID NO:5 or SEQ ID NO: 6.

4. The vaccine of claim 1, wherein the vaccine comprises more than one copy of the first polynucleotide sequence, more than one copy of the second polynucleotide sequence or both.

5. The vaccine of claim 1, wherein the first polynucleotide sequence is in frame to the second polynucleotide sequence.

6. The vaccine of claim 1, wherein the vector is selected from the group consisting of a virus, a bacterium, and a liposome.

7. The vaccine of claim 6, wherein the vector is a bacterium.

8. The vaccine of claim 7, the bacterium comprising the TRAP polypeptide on its surface.

9. The vaccine of claim 7, wherein the bacterium is selected from the group consisting of *Salmonella* species, *Bacillus* species, *Escherichia* species, and *Lactobacillus* species.

10. The vaccine of claim 1, wherein the first polynucleotide is inserted into a polynucleotide sequence encoding an external portion of a transmembrane protein.

11. A method of enhancing the immune response against an Apicomplexan parasite in a subject comprising administering to the subject the vaccine of claim 1 in an amount effective to enhance the immune response of the subject to the Apicomplexan parasite.

12. The method of claim 11, wherein the vaccine is comprised within a vector selected from the group consisting of a virus and a bacterium.

30

13. The method of claim 11, wherein the TRAP polypeptide is SEQ ID NO:2.

14. The method of claim 12, wherein the vector is selected from the group consisting of *Salmonella* species, *Bacillus* species, *Escherichia* species, and *Lactobacillus* species.

15. The method of claim 11, wherein the vaccine is administered by a method selected from the group consisting of oral, intranasal, parenteral, and in ovo.

16. The method of claim 11, wherein the enhanced immune response comprises an enhanced antibody response or an enhanced T cell response.

17. The method of claim 11, wherein the subject is member of a poultry species or a mammal.

18. The method of claim 12, wherein the vector comprising the vaccine is killed prior to administration to the subject.

19. The method of claim 12, wherein the vector comprising the vaccine is not capable of replicating in the subject.

20. The method of claim 11, wherein the Apicomplexan parasite is selected from the group consisting of *Eimeria*, *Plasmodium*, *Toxoplasma*, and *Cryptosporidium*.

21. A method of reducing morbidity associated with infection with an Apicomplexan parasite in a subject comprising administering to the subject the vaccine of claim 1 in an amount effective to enhance the immune response of the subject to the Apicomplexan parasite.

22. The vaccine of claim 1, wherein the CD154 polypeptide is expressed on the surface of the vector.

23. The vaccine of claim 22, wherein the TRAP polypeptide is expressed on the surface of the vector.

24. The vaccine of claim 1, wherein the second polynucleotide is inserted into a polynucleotide sequence encoding an external portion of a transmembrane protein.

25. The vaccine of claim 24, wherein the first polynucleotide is inserted into a polynucleotide sequence encoding an external portion of a transmembrane protein.

26. The vaccine of claim 24, wherein the first polynucleotide encodes the polypeptide of SEQ ID NO: 2 and wherein the second polynucleotide encodes the polypeptide of SEQ ID NO: 4 or SEQ ID NO: 5.

* * * * *